Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 2

Status

Completed 2Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 5NIH 3

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 4Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Multiple Myeloma 130Recurrence 34Lymphoma, Follicular 28Lymphoma, Large B-Cell, Diffuse 27Lymphoma, Non-Hodgkin 23Neoplasms 13Lymphoma 13Lymphoma, Mantle-Cell 11Lymphoma, B-Cell, Marginal Zone 11Leukemia, Lymphocytic, Chronic, B-Cell 11Hematologic Diseases 5Neoplasms, Plasma Cell 4Myelodysplastic Syndromes 4Lymphoma, B-Cell 4Hematologic Neoplasms 4Neoplasm Metastasis 3Melanoma 3Leukemia, Myeloid, Acute 3Pyloric Stenosis, Hypertrophic 2Prostatic Neoplasms 2Paraproteinemias 2Ovarian Neoplasms 2Lymphoproliferative Disorders 2Lymphoma, T-Cell, Peripheral 2Leukemia-Lymphoma, Adult T-Cell 2Leukemia, B-Cell 2Leukemia 2Immunoproliferative Disorders 2Hodgkin Disease 2Carcinoma, Non-Small-Cell Lung 2

Interventions

Brentuximab Vedotin 20Rituximab 10pirtobrutinib 7dacetuzumab 7Doxorubicin 6ruxolitinib 5Vincristine 5Prednisone 5Lenalidomide 5Cyclophosphamide 5ponatinib 4Imatinib Mesylate 4Dexamethasone 4Bendamustine Hydrochloride 4Azacitidine 4nilotinib 3lintuzumab 3Bortezomib 3vosaroxin 2venetoclax 2spartalizumab 2pomalidomide 2ibrutinib 2Rifampin 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2KW-2478 2Ifosfamide 2Gemcitabine 2Etoposide 2Dacarbazine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Hematologic Diseases × Lenalidomide × Clear all
NCT05317416 2026-04-16

MagnetisMM-7

Pfizer

Phase 3 Active not recruiting
854 enrolled
Plasma cell

Hematologic Diseases, Multiple Myeloma

NCT05641324 2024-02-12

A Study of ANV419 Alone or in Combination With Approved Treatments in Patients With Multiple Myeloma (OMNIA-2)

Anaveon AG

Phase 1 Terminated
4 enrolled
Plasma cell

Disease, Hematologic Diseases, Multiple Myeloma, Neoplasms, Recurrence

NCT02155634 2018-04-10

Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma

Celgene

Phase 3 Withdrawn
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Paraproteinemias

NCT00525447 2014-10-09

Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma

Seagen Inc.

Phase 1 Completed
36 enrolled
LymphoidPlasma cell

Blood Coagulation Disorders, Hematologic Diseases, Hemorrhagic Disorders, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Paraproteinemias, Vascular Diseases, Hemostatic Disorders

NCT00502112 2011-10-12

A Phase I Study of Lintuzumab Combined With Lenalidomide in Patients With Myelodysplastic Syndromes (MDS)

Seagen Inc.

Phase 1 Completed
13 enrolled
MyeloidOther hematologic neoplasm

Hematologic Diseases, Myelodysplastic Syndromes, Preleukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡